Skip to main content
SpringerLink
Log in

Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy

  • Chapter
Urological Oncology

  • 752 Accesses

Abstract

One of the important issues in the use of cytotoxic chemotherapy is the timing of treatment. When considering chemotherapy for “hormone-refractory” prostate cancer, one must ensure that the cancer is really resistant to the impact of castration. Adrenal androgens contribute to the hormonal environment, so that some tumors that appear to be resistant or refractory to the castrate, testoster-one-depleted setting, may actually be receiving stimulation from adrenal hormones, and will thus respond to second-line adrenal blockers, such as aminoglutethimide or ketoconazole. These remissions sometimes may be sustained for months to years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013–1021.

    CAS  PubMed  Google Scholar 

  2. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 1988;15:371–389.

    CAS  PubMed  Google Scholar 

  3. Petrylak D, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl JMed 2004;351:1513–1520.

    Article  CAS  Google Scholar 

  4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.

    Article  CAS  PubMed  Google Scholar 

  5. Slack NH. Results of chemotherapy protocols of the US National Prostatic Cancer Project (NPCP). Clin Oncol 1983;2:441–459.

    Google Scholar 

  6. Kelly WK, Scher HI, Mazumdar M. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11: 607–615.

    CAS  PubMed  Google Scholar 

  7. Sridhara R, Eisenberger MA, Sinibaldi V, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995;13:2944–2953.

    CAS  PubMed  Google Scholar 

  8. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461–3467.

    CAS  PubMed  Google Scholar 

  9. Petrylak D, Ankerst D, Jiang C, et al. Evaluation of post treatment PSA declines for surrogacy using Prentice’s criteria in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516–521.

    Article  PubMed  Google Scholar 

  10. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J. Clin. Oncol 1999;17:1654–1663.

    CAS  PubMed  Google Scholar 

  11. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14: 1756–1764.

    CAS  PubMed  Google Scholar 

  12. Browman GP. Science, language, intuition, and the many meanings of quality of life. J Clin Oncol 1999;17:1651–1653.

    CAS  PubMed  Google Scholar 

  13. Beer T, Raghavan D. Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder. Prostate 2000;45:184–193.

    Article  CAS  PubMed  Google Scholar 

  14. Raghavan D, Brandes LJ, Klapp K, et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol 2005;174:1808–1813.

    Article  CAS  PubMed  Google Scholar 

  15. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156–3163.

    CAS  PubMed  Google Scholar 

  16. Savarese D, Taplin ME, Halabi S, et al. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol 1999;26(suppl 17):39–44.

    CAS  PubMed  Google Scholar 

  17. Petrylak DP, Shelton GB, England-Owe C, et al. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPCA). Proc ASCO 2000;19:334a(abstract 1312).

    Google Scholar 

  18. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44–53.

    CAS  PubMed  Google Scholar 

  19. Urakami S, Igawa M, Kikuno K, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168:2444–2450.

    Article  CAS  PubMed  Google Scholar 

  20. DiPaola RS, Rinehart J, Nemunaitis J, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20:1874–1879.

    Article  CAS  PubMed  Google Scholar 

  21. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439–1446.

    Article  CAS  PubMed  Google Scholar 

  22. Wang J, Halford S, Rigg A, et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675–680.

    Article  CAS  PubMed  Google Scholar 

  23. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63:1138–1142.

    Article  PubMed  Google Scholar 

  24. Raghavan D, Coorey G, Rosen M, Page J, Farebrother T. Management of hormone-resistant prostate cancer: an Australian trial. Semin Oncol 1996;23(suppl 14):20–23.

    CAS  PubMed  Google Scholar 

  25. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506–2513.

    CAS  PubMed  Google Scholar 

  26. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335–3342.

    Article  CAS  PubMed  Google Scholar 

  27. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose alone in patients with asymptomatic, hormone refractory prostate cancer. J Urol 2002;168:2451–2453.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA

    Derek Raghavan MD, PhD, FACP, FRACP

Authors
  1. Derek Raghavan MD, PhD, FACP, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St. Bartholomew’s and Homerton Hospitals Queen Mary Barts and the London School of Medicine and Dentistry, University of London, London, UK

    Vinod H. Nargund PhD, FRCS (Urol), FEBU (Chair, Uro-Oncology MDT and Consultant Urological Surgeon) (Chair, Uro-Oncology MDT and Consultant Urological Surgeon)

  2. Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Derek Raghavan MD, PhD, FACP, FRACP (Chairman and Director) (Chairman and Director)

  3. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA

    Howard M. Sandler MD (Professor and Senior Associate Chair) (Professor and Senior Associate Chair)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Raghavan, D. (2008). Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy. In: Nargund, V.H., Raghavan, D., Sandler, H.M. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-1-84628-738-1_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-738-1_31

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-387-1

  • Online ISBN: 978-1-84628-738-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation